Table 5

 Number of adverse events in four clinical trials of infliximab in systemic vasculitis (including patients with Wegener’s granulomatosis (WG))

Severe adverse eventsInfectionsDeaths
*One death was eight weeks after stopping infliximab.
Booth et al, 200232000
Bartolucci et al, 200233000
Lamprecht et al, 200234000
Booth et al, 2004351062*
Total10 (19%)6 (11%)2 (4%)